A3312712
Dasatinib , ≥99% , 302962-49-8
Synonym(s):
BMS 354825;BMS354825;BMS-354825;N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
CAS NO.：302962-49-8
Empirical Formula: C22H26ClN7O2S
Molecular Weight: 488.01
MDL number: MFCD11046566
EINECS: 801-607-0
| Pack Size | Price | Stock | Quantity |
| 25MG | RMB31.20 | In Stock |
|
| 100MG | RMB39.20 | In Stock |
|
| 500MG | RMB111.20 | In Stock |
|
| 1G | RMB148.80 | In Stock |
|
| 5G | RMB552.80 | In Stock |
|
| 25g | RMB2047.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 275-286°C |
| Density | 1.408±0.06 g/cm3(Predicted) |
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | Soluble in DMSO (up to 200 mg/ml). |
| pka | 10.94±0.70(Predicted) |
| form | White powder. |
| color | White or off-white |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months. |
| InChIKey | ZBNZXTGUTAYRHI-UHFFFAOYSA-N |
| SMILES | S1C(C(NC2=C(C)C=CC=C2Cl)=O)=CN=C1NC1C=C(N2CCN(CCO)CC2)N=C(C)N=1 |
Description and Uses
Dasatinib, developed and marketed by Bristol Myers, is the first approved oral tyrosine kinase inhibitor which binds to multiple conformations of ABL kinase for the treatment of two leukemia indications: chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib is a highly potent, ATPcompetitive ATPcompetitive kinase inhibitor which, at nanomolar concentrations, inhibits BCR-ABL, SRC family, c-KIT, EPHA2 and PDGFR-B.
Safety
| Symbol(GHS) |    GHS05,GHS08,GHS09 |
| Signal word | Danger |
| Hazard statements | H315-H318-H351-H361fd-H372-H410 |
| Precautionary statements | P202-P273-P280-P302+P352-P305+P351+P338-P308+P313 |
| HS Code | 29341000 |
